OCUL
NASDAQOcular Therapeutix Inc.
Price$7.39+0.04 (+0.54%)
01:30 PM07:45 PM
News · 26 weeks50-25%
2026-04-192026-10-11
Mix1990d
- Insider8(42%)
- Other6(32%)
- SEC Filings3(16%)
- Earnings1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Ocular Therapeutix Inc.4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- ANALYSTUBS initiated coverage on Ocular Therapeutix with a new price targetUBS initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $14.00
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of
- INSIDERSEC Form 4 filed by Ocular Therapeutix Inc.4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERSEC Form 4 filed by Ocular Therapeutix Inc.4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ to Participate in October Scientific and Investor ConferencesBEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference: Chardan 10th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of September 14, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 64,850 shares of
- PROcular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMDConsistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company’s application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to potentially be the first TKI approved for wet AMD BEDFORD, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company commit
- INSIDERChief Operating Officer Notman Donald sold $11,254 worth of shares (1,099 units at $10.24), decreasing direct ownership by 0.30% to 366,529 units (SEC Form 4) to cover withholding tax4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ to Participate in September and October Investor and Scientific ConferencesBEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026. Upcoming Investor Conferences: Wells Fargo 21st Annual Healthcare Conference:Date: Thursday, September 10, 2026Ocular Therapeutix to host investor one-on-one meetingsLocation: Boston, MA Baird 2026 Global Healthcare Conference:Date: Tuesday, September 15, 2026Fireside Chat: 10:50 – 11:20 AM EDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY A
- INSIDERChief Development Officer Kaiser Peter sold $32,687 worth of shares (3,035 units at $10.77), decreasing direct ownership by 1% to 264,378 units (SEC Form 4) to cover withholding tax4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Scientific Officer Heier Jeffrey S. sold $35,531 worth of shares (3,296 units at $10.78), decreasing direct ownership by 1% to 318,326 units (SEC Form 4) (withholding tax)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Strategy Officer Nayak Sanjay sold $20,450 worth of shares (1,897 units at $10.78), decreasing direct ownership by 0.58% to 326,898 units (SEC Form 4) (withholding tax)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDEROfficer Dugel Pravin sold $233,160 worth of shares (21,649 units at $10.77), gifted 50,092 shares and received a gift of 50,092 shares, decreasing direct ownership by 0.85% to 2,525,429 units (SEC Form 4) (for withholding tax)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of August 3, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 53,975 shares of Ocul
- SECSEC Form S-8 filed by Ocular Therapeutix Inc.S-8 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- SECSEC Form 10-Q filed by Ocular Therapeutix Inc.10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- SECOcular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- PROcular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business HighlightsOcular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be based on SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence Pre-NDA meeting scheduled with FDA in Q3 2026 with the NDA submission to follow the Section 505(b)(2) pathway which could accelerate the review timeline by up to 60 days New Post Hoc SOL-1 analysis demonstrates up to an estimated 72% reduction in treatment burden over 60 weeks with AXPAXLI as compar
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 34,700 shares of Ocular’s com
- PROcular Therapeutix™ to Participate in July Scientific and Investor ConferencesBEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences: 9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDTPresenter: Peter K. Kaiser, MD, Chief Development Officer Panel Title: The Impact of Recent FDA Guidance on Drug DevelopmentPanel Date/Time: Tuesday, July
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of a non-statutory stock option award to purchase up t
- INSIDEROfficer Dugel Pravin gifted 50,092 shares and received a gift of 50,092 shares, decreasing direct ownership by 2% to 2,547,078 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026 SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at Week 96 as a key secondary endpoint of the SOL-R trial SOL-R to remain masked through Week 96, with topline results now expected in 1Q 2028 New secondary endpoint addition to SOL-R has
- INSIDERDirector Warden Charles M was granted 14,000 shares, increasing direct ownership by 16% to 100,464 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
OCUL FAQ
7 questionsWhat does Ocular Therapeutix Inc. do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the...Where does OCUL stock trade?
Ocular Therapeutix Inc. (OCUL) is listed on NASDAQ.What sector and industry is OCUL in?
Ocular Therapeutix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ocular Therapeutix Inc. go public?
Ocular Therapeutix Inc. (OCUL) completed its IPO in 2014.What are analysts saying about OCUL?
Ocular Therapeutix Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $1400.00 price target on 2026-10-12. Recent price targets range from $1100.00 to $2100.00.What companies are similar to OCUL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OCUL side-by-side with any of them on Quantisnow.How can I track OCUL on Quantisnow?
Quantisnow aggregates Ocular Therapeutix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCUL to receive live email and push alerts on every new disclosure.